Navigation Links
AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Date:2/12/2008

an open-label, non-comparative multi-center Phase 2 trial will have as its primary endpoint the partial or complete tumor response rate according to RECIST and/or GCIG guidelines. Secondary endpoints will include time to progression, survival, toxicity as well as adverse effects. The trial will include up to 82 patients (up to 41 with a diagnosis of platinum-resistant ovarian cancer and up to 41 with disseminated endometrial cancer). Patients will be administered an intravenous infusion of 267 mg/m2 of AEZS-108 over a period of 2 hours at a constant rate, every Day 1 of a 21-day (3-week) cycle. The proposed duration of the study treatment is six, three-week cycles. The planned study period is approximately 24 months. Further information on the trial is available at http://www.clinicaltrials.gov.

Prior Phase 1 trial results

On June 3, 2007 positive results of an open, multi-center, sequential group, dose-escalation Phase 1 study in various gynaecological cancers were presented at the American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, Illinois. 17 patients with LHRH-receptor positive gynaecological cancers were recruited. AEZS-108 was administered by intravenous infusion over two hours at dosages of 10, 20, 40, 80, 160 and 267 mg/m2. At 160 mg/m2, six patients had a total of 32 cycles and at 267 mg/m2, seven patients had a total of 27 cycles. Most of the patients had been pretreated with various chemotherapies.

The study showed that AEZS-108 was well tolerated by patients with gynaecological tumors. Furthermore, AEZS-108 is the first drug in a clinical study that targets the cytotoxic activity of doxorubicin specifically to LHRH-receptor expressing tumors. Finally, signs of anti-tumor activity were observed in three out of 13 patients treated with 160 or 267 mg/m2 of AEZS-108, including three patients with complete or partial response.

About AEZS-108

AEZ
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
2. AEterna Zentaris Announces Outcome of Managements Strategic Review
3. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
4. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Immtech Reports Fiscal Third Quarter 2008 Results
7. Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out
8. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
9. Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
10. Bunge Reports Fourth Quarter Net Income of $245 Million
11. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... October 19, 2014 The Asian Automatic ... Asian with analysis and forecast of revenue. The Automatic ... to around $463.9 million by 2018, at a developing ... through the TOC of the Asian Automatic patient billing ... provided. This also provides a glimpse of the segmentation ...
(Date:10/19/2014)... October 19, 2014 The report "Chocolate, ... Share, Trade, Prices, Geography Trend and Forecast (2011 - ... category, and geography and studies the major market drivers, ... America, Europe, and Asia. , The global chocolate market ... $98.3 billion in 2016 at an estimated CAGR of ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The ... Defense, & Homeland Security), Technology, Payload, Type & ... and segments the global unmanned ground vehicle market ... and forecasting of market sizes. The report also ... and opportunities impacting it along with the adoption ...
(Date:10/18/2014)... The “Human Insulin Market- by Product Type, [Human ... Insulin (Rapid Acting, Long Acting, Premixed)], by Brand ... Forecast to 2018” provides a detailed overview of ... trends, and strategies impacting the global human insulin ... the revenue and share analysis. , The global ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... , ... , , , , ... 2100 bioanalyzer can,be used in combination with Standardized RT (StaRT)-PCR ... obtain highly reproducible, standardized gene expression,measurement with RT-PCR. The internal ...
... , , ... , , , This Application ... kit can be used to detect cell surface,and intracellular protein targets ... staining on CCRF-CEM cells and intracellular,glucocorticoid receptor (GR) staining of H4 ...
... , ... , , This Application Note describes ... be used to determine the efficiency,of transfection of mammalian cells using ... with,expression vectors encoding GFP from two different sources, and optimization,of transfection ...
Cached Biology Technology:Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 2Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 3Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 4Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 5Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 6Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 7Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 2Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 3Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 4Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 5Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 6Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 7Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 8Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 2Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 3Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 4Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 5Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 6Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 7
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... research team has discovered a new kind of stem cell ... that lines liver blood vessels, according to a study published ... existence of such a cell type contradicts current theory on ... may hold clues to origins of, and future treatment for, ... single cell into a complex being made up of more ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... scientists at the University of Minnesota Medical School and ... and made suggestions on how to advance research and ... published in the January 2008 issue of the Lancet ... , Many neurological disorders are difficult to treat because ...
... and the National Center for Ecological Analysis and Synthesis ... predict gene flow across landscapes. Their approach could give ... for wildlife corridors, which are crucial to protecting biodiversity. ... theory and ecological connectivity, said Brad McRae, head of ...
... the University of California, San Diego have discovered a ... in the gene are present in both the female ... a paper that appears online today in the journal ... consent mutation because of its unusual properties. Mutations ...
Cached Biology News:International scientists tackle obstacles to treating brain disorders 2International scientists tackle obstacles to treating brain disorders 3Model connects circuit theory to wildlife corridors 2Biologists find unusual plant gene: abstinence by mutual consent 2Biologists find unusual plant gene: abstinence by mutual consent 3
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
CHIMAERIC HUMAN IgA2 ANTI NP...
... Cloning Kit includes the pZErO-2 ... selection in E. coli. The ... to eliminate high background. The ... reagents you need for simple ...
Biology Products: